Company Overview
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
Why Investors Should Care
Generates a return on equity of 40.3%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +9.55% |
| 6 Months: | +6.64% |
| 3 Months: | +54.32% |
| 1 Month: | +14.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)72.14 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 40.3%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SGP SpyGlass Pharma, Inc. PHARMA | 28.92 | -17.32 | $967.32M | 0.00% | -38.64% | 40.34% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 7.75M | 7.42M | 13.63M | 15.41M |
| Operating Income | -7.75M | -7.42M | -13.63M | -15.41M |
| EBITDA | -7.65M | -7.30M | -13.41M | -15.09M |
| Interest Expense | - | - | - | - |
| Pretax Income | -8.40M | -8.82M | -12.56M | -13.82M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -8.40M | -8.82M | -12.56M | -13.82M |
| Diluted EPS | - | -0.49 | - | -0.69 |
| R&D Expense | - | 6.05M | - | 8.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 14.23M | 27.06M | 41.45M |
| Operating Income | -14.23M | -27.06M | -41.45M |
| EBITDA | -14.11M | -26.79M | -40.84M |
| Interest Expense | - | - | - |
| Pretax Income | -13.32M | -29.16M | -39.87M |
| Tax Provision | 0 | 0 | 0 |
| Net Income | -13.32M | -29.16M | -39.87M |
| Diluted EPS | -1.17 | -1.62 | -1.25 |
| R&D Expense | - | 19.98M | 29.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 41.15M | 23.32M | 115.87M |
| Current Assets | 40.61M | 17.41M | 108.77M |
| Cash & Equivalents | 15.85M | 16.27M | 96.36M |
| Inventory | - | - | - |
| Receivables | 122.91K | 423.00K | 431.00K |
| Total Liabilities | 74.13M | 83.79M | 214.70M |
| Current Liabilities | 1.59M | 7.79M | 8.58M |
| Long Term Debt | - | - | - |
| Total Debt | 0 | 3.90M | 1.58M |
| Total Equity | -32.99M | -60.47M | -98.84M |
| Shares Outstanding | 31.91M | 31.91M | 31.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -12.28M | -22.03M | -32.70M |
| Investing Cash Flow | -20.49M | 22.26M | -11.79M |
| Financing Cash Flow | 39.77M | 185.00K | 124.58M |
| Capital Expenditure | -216.54K | -1.99M | -789.00K |
| Free Cash Flow | -12.49M | -24.02M | -33.49M |
| Net Change in Cash | 7.01M | 419.00K | 80.09M |
| Share Buybacks | - | 0 | 1.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 40.4% | 48.2% | 40.3% |
| ROCE % | -36.0% | -174.3% | -38.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 23.99% | 8.02M | $233.25M |
| 2 | NEA Management Company, LLC | 22.11% | 7.39M | $214.97M |
| 3 | Sands Capital Alternatives, LLC | 7.48% | 2.50M | $72.70M |
| 4 | Samsara BioCapital, LLC | 6.31% | 2.11M | $61.36M |
| 5 | Blackrock Inc. | 2.13% | 711.71K | $20.70M |
| 6 | Price (T.Rowe) Associates Inc | 2.02% | 674.14K | $19.60M |
| 7 | Vestal Point Capital, LP | 2.00% | 670.00K | $19.48M |
| 8 | JPMORGAN CHASE & CO | 1.88% | 629.74K | $18.31M |
| 9 | Deerfield Management Company, L.P | 1.65% | 550.00K | $15.99M |
| 10 | Millennium Management Llc | 1.52% | 507.26K | $14.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SGP
SpyGlass Pharma to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate …
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
SpyGlass Pharma, a biopharmaceutical clinical-stage company dedicated to transforming treatment for patients living with chronic eye conditions, today celebrated the grand opening of its new Irvine headquarters, marking a pivotal point in t…
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing. Mr. Pinder br…
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
Additional supportive reimbursement pathway for surgeons may enhance patient access to the BIM-IOL System upon potential commercializationALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Ph…
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Topline 12-month data from the BIM-IOL System Phase 1/2 trial demonstra…
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track…
SGP — Frequently Asked Questions
What is the current share price of SpyGlass Pharma, Inc. (SGP)?
As of 2026-09-19 21:16 PDT, SpyGlass Pharma, Inc. (SGP) trades at $28.92 on NasdaqGS. Its 52-week range is $17.56 to $29.68.
What is the market capitalisation of SGP?
SpyGlass Pharma, Inc. (SGP) has a market capitalisation of $967.32M on NasdaqGS.
What is the P/E ratio of SGP?
SGP trades at a trailing price-to-earnings (P/E) ratio of -17.32. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.19.
What is the return on equity (ROE) of SGP?
SGP has a return on equity (ROE) of 40.34%. Its return on capital employed (ROCE) is -38.64%.
Is SGP a good stock to buy?
This page provides a data-driven analysis of SpyGlass Pharma, Inc. (SGP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.